| Ytd | -4.72% | |
| 1y | -93.24% |
| Open | 10.51 | Prev Close | 10.15 | Low | 10.51 | High | 11.28 | Mkt Cap | 176.58K |
| Vol | 17.97K | Avg Vol | 15.67K | EPS | -24.82 | P/E | -0.43 | Forward P/E | -2.45 |
| Beta | 1.10 | Short Ratio | 4.12 | Inst. Own | 29.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 10.62 | 200-d Avg | 12.17 | 1yr Est | 18.00 |
NVNO News
Published economic health study shows both short- and long-term cost-effectiveness of replacement ve
Published economic health study shows both short- and long-term cost-effectiveness of replacement ve
enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(5.37) per share. This is a 53.51 percen
Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivot
CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe
New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous V
- Live webcast on Wednesday, June 24th at 2:00 PM ET - Access the event here IRVINE, CA / ACCESS New
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June
First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE
Company ended the first quarter with approximately $25 million in cash and investments Capital on ha
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and
Company accelerated development of the enVVe® System, completing pre-clinical studies and progressin
NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund
Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free R
LENSAR (NASDAQ: LNSR - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free Report) are bot
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter
enVVeno Medical Corporation (NASDAQ: NVNO)'s stock is going to reverse split on the morning of Tuesd
IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVen
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, Decem
IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVe
- Cash and investments are sufficient to fund current operations through Q2 2027, not including Veno
Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno M
On Wednesday, 129 stocks made new 52-week lows.
Wednesday's session saw 269 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 348 companies hit new 52-week lows.